SIGN UP
LOG IN
MARKET
RDHL
RDHL
Redhill Biopharm
NASDAQ
1.310
+0.030
+2.34%
After Hours: 1.400 +0.09 +6.86% 19:59 12/08 EST
OPEN
1.290
PREV CLOSE
1.280
HIGH
1.420
LOW
1.210
VOLUME
2.14M
TURNOVER
0
52 WEEK HIGH
11.50
52 WEEK LOW
0.2570
MARKET CAP
14.50M
P/E (TTM)
-0.3136
1D
5D
1M
3M
1Y
5Y
Organovo, Fortress Biotech among healthcare movers
Organovo, fortress biotech among healthcare movers. S&p 500 health care sector -0.39% to 1528.18. Universe pharmaceuticals, solid biosciences and inogen are among the gainers. Zvsa and zyversa therapeutics among the losers.
Seeking Alpha · 2d ago
Redhill Biopharm: Report of foreign issuer
Press release · 4d ago
RedHill secures funding for Phase 2 study of COVID-19 treatment
Healthcare redhill secures funding for phase 2 study of early covid-19 treatment. $4.8m in funding will cover the entirety of the rhb-107 arm of the aceso protect study. Redhill's oral antiviral drug could provide an option to pfizer's paxlovid.
Seeking Alpha · 6d ago
Redhill Biopharm: Report of foreign issuer
Press release · 6d ago
RedHill Reveals New, Non-Dilutive External Funding Of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
The 300-patient phase 2 rhb-107 arm of the protect study has received fda clearance to start. The study is being conducted in the u.s., thailand, ivory coast, south africa and uganda. $4.8 million in additional funding will fund the study.
Benzinga · 6d ago
Weekly Report: what happened at RDHL last week (1127-1201)?
Weekly Report · 6d ago
Redhill Biopharm: Report of foreign issuer
Press release · 12/01 22:12
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Benzinga's stock whisper index highlights five stocks that warrant attention each week. Bitcoin mining company marathon digital holdings saw strong interest from investors on the week. Vivos therapeutics received fda clearance for a sleep apnea treatment. Farfetch limited and gamestop corporation saw increased interest.
Benzinga · 12/01 18:39
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Webull offers RedHill Biopharma Ltd (ADR) stock information, including NASDAQ: RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.